top of page

Radius Health partners with Novartis to evaluate RAD1901 combination regimens in advanced breast can

Radius Health has entered into a worldwide clinical collaboration with Novartis Pharmaceuticals to evaluate the safety and efficacy of combining investigational agent RAD1901, a novel oral selective estrogen receptor degrader (SERD), with investigational agent LEE011 (ribociclib), a cyclin-dependent kinase (CDK) 4/6 inhibitor.

Click on this link for more information.


Today's News
Follow us
  • LinkedIn Social Icon
  • Vimeo Social Icon
Newsletter on Pharma Legislation
the newsletter of
bottom of page